AIDS detox treatment instrument

Abstract

An AIDS detoxification treatment instrument used in the medical field, characterized in that it prepares a blood and plasma separator capable of separating plasma, single blood cells and multinucleated giant cells formed by inhabiting HIV, and prepares HIVgp120 antibodies and HIVgp41 antibodies that can bind HIV As well as HIV gp120 and gp41 antibodies combined with goat anti-Ig, and hybridoma macrophage cell lines, as purifiers, prepared in agar gel, wrapped with polymer materials to make a purifier, and together with the separator constitute the key to the extracorporeal blood circulation device When the blood flows through the blood separator, the multinucleated giant cells containing HIV are filtered out, and then when the plasma separated by the plasma separator flows through the purifier, the HIV in it is absorbed and removed by the purifier, and the purified plasma and plasma The single blood cells separated by the separator are confluent and then reinfused into the body, so as to achieve the purpose of AIDS blood purification treatment to remove HIV inside and outside the blood cells.

Description

Technical field [0001] The invention relates to the preparation and application of an AIDS detoxification therapeutic apparatus in the field of biomedicine, which is mainly used for removing HIV in and out of blood cells of AIDS patients, thereby achieving the purpose of preventing, controlling and treating AIDS. Background technique [0002] AIDS is an infectious disease caused by the Human Immunodeficiency Virus (HIV), which is widespread worldwide. According to the relevant reports of the World Health Organization (WHO) and the UNAIDS, since the first case of AIDS was discovered in the United States in 1981 So far, 208 countries and regions around the world are seriously threatened by AIDS. About 40 million people are infected with AIDS, and the death toll has exceeded 20 million. Every day, about 6000 people become HIV-infected, and about 300 people die every day. In AIDS. The number of HIV-infected persons in China is in a period of rapid growth, and currently far exceeds 1...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, or it will mediate the ADCC effect to dissolve the cellular antigen by activating complement, but HIV does not Cellular antigens; either attract phagocytes to engulf antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and make them lose their infectivity, but the structure of HIV antigens is variable, often make it difficult for antibodies to recognize

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0009] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images